PROSPECTIVE, RANDOMIZED TRIAL OF THE EFFECT OF ANTIBODY INDUCTION IN SIMULTANEOUS PANCREAS AND KIDNEY TRANSPLANTATION: THREE-YEAR RESULTS1
Authors:
- George W. BurkeGBGeorge W. Burke
- Dixon B. KaufmanDKDixon B. Kaufman
- J. Michael MillisJMJ. Michael Millis
- A. Osama GaberAGA. Osama Gaber
- Christopher P. JohnsonCJChristopher P. Johnson
- David E. R. SutherlandDSDavid E. R. Sutherland
- Jeffrey D. PunchJPJeffrey D. Punch
- Barry D. KahanBKBarry D. Kahan
- Eugene SchweitzerESEugene Schweitzer
- Alan LangnasALAlan Langnas
- James PerkinsJPJames Perkins
- John ScandlingJSJohn Scandling
- 1 April 2004
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Transplantation
- Vol. 77 (8) , 1269-1275
Abstract
Historically, antibody induction has been used because of the higher immunologic risk of graft loss or rejection observed in simultaneous pancreas and kidney (SPK) transplantation compared with kidney transplantation alone. This trial was designed to assess the effect of antibody induction in SPK transplant recipients receiving tacrolimus, mycophenolate mofetil, and corticosteroids. Induction agents included T-cell–depleting and interleukin-2 receptor antibodies. A total of 174 SPK transplant recipients were enrolled in a prospective, open-label, multi-center study. They were randomized to induction (n=87) or non-induction (n=87) groups and followed for 3 years. At 3 years, actual patient (94.3% and 89.7%) and pancreas (75.9% and 75.9%) survivals were similar between the induction and non-induction groups, respectively. Actual kidney survival was similar at 1 and 2 years, but at 3 years, it was significantly better in the induction group compared with the non-induction group (92% vs. 81.6%; P =0.04). At 3 years, median serum creatinine and hemoglobin A1C were similar between the induction and non-induction groups (1.35 mg/dL and 1.20 mg/dL, 5.4% and 5.5%, respectively). Three-year cumulative incidence of biopsy-confirmed, treated acute kidney rejection in the induction and non-induction groups was 19.5% and 27.5% (P =0.14), respectively, with odds 4.6 times greater in African Americans regardless of treatment (P =0.004). Significantly higher rates of cytomegalovirus (CMV) viremia and CMV syndrome occurred in those receiving T-cell–depleting antibody induction (36.1%) when compared with those receiving anti–interleukin-2 receptor antibodies (2%) and non-induction (8.1%) (P <0.0001). Tacrolimus, mycophenolate mofetil, and corticosteroids resulted in excellent safety and efficacy in SPK transplant recipients. Actual 3-year kidney survival was significantly better in the induction group; however, CMV viremia and CMV syndrome rates were significantly higher in the T-cell–depleting antibody group. African Americans demonstrated a significantly greater risk of acute rejection despite antibody induction. Decisions regarding the use of induction therapy must weigh the risk of kidney graft loss or rejection against the risk of infection.Keywords
This publication has 12 references indexed in Scilit:
- Tacrolimus versus cyclosporine in primary simultaneous pancreas-kidney transplantation: preliminary results at 1 year of a large multicenter trialTransplantation Proceedings, 2002
- Surgical Techniques for Pancreas TransplantationEuropean Surgery, 2001
- MYCOPHENOLATE MOFETIL AND TACROLIMUS AS PRIMARY MAINTENANCE IMMUNOSUPPRESSION IN SIMULTANEOUS PANCREAS-KIDNEY TRANSPLANTATIONTransplantation, 1999
- A STUDY COMPARING MYCOPHENOLATE MOFETIL TO AZATHIOPRINE IN SIMULTANEOUS PANCREAS-KIDNEY TRANSPLANTATION1Transplantation, 1998
- Use of Tacrolimus and Mycophenolate Mofetil For Pancreas–Kidney Transplantation With or Without OKT3 InductionTransplantation Proceedings, 1998
- Tacrolimus/Mycophenolate Provides Superior Immunosuppression Relative to Neoral/Mycophenolate in Synchronous Pancreas-Kidney TransplantationTransplantation Proceedings, 1998
- Pancreas Transplantation Without Antibody TherapyTransplantation Proceedings, 1998
- Simultaneous Pancreas/Kidney Transplantation: Comparison of Mycophenolate Mofetil Versus AzathioprineTransplantation Proceedings, 1998
- Mycophenolate Mofetil and Tacrolimus for Induction and Maintenance Therapy After Pancreas TransplantationTransplantation Proceedings, 1998
- MYCOPHENOLATE MOFETIL DECREASES REJECTION IN SIMULTANEOUS PANCREAS-KIDNEY TRANSPLANTATION WHEN COMBINED WITH TACROLIMUS OR CYCLOSPORINE1Transplantation, 1997